Healthcare Provider Clariane Launches €230 Million Offering to Restructure Costly Debt
Paris, Tuesday, 28 April 2026.
European healthcare provider Clariane is issuing €230 million in new notes to strategically replace older bonds currently burdening the company with a staggering 13.168% annual interest rate.
The Mechanics of the Refinancing Strategy
On April 28, 2026, Clariane officially launched its proposed offering of €230 million in additional euro-denominated senior notes [1]. These instruments, which carry a 6.875% interest rate and mature in 2031, are designed to be fully fungible with the company’s existing debt [1]. Specifically, they will be issued under an existing indenture dated April 16, 2026, which already governs €500 million of identical senior notes [1]. By consolidating these issuances, the total principal amount under this specific class of notes will reach 730 million [1].
Negotiating New Leverage Covenants
Executing this refinancing required strategic negotiations with Clariane’s existing lenders. The company’s syndicated credit facility lenders agreed to allow the replacement of hybrid IFRS-equity instruments with standard debt instruments, contingent upon a revised “Wholeco” leverage ratio [1]. The maximum allowable threshold for this ratio was subsequently increased to 6.0x, up from the previously established 5.0x limit [1]. This adjustment provides the company with the necessary breathing room to restructure its balance sheet without triggering default clauses [1].
Future Financial Targets and Market Restrictions
Looking ahead, Clariane has secured a structured glide path for its financial covenants. The maximum permitted leverage will be set at 7.5x as of June 30, 2026, before progressively tightening [1]. The covenant drops to 7.0x for the periods ending December 31, 2026, and June 30, 2027, then to 6.5x through June 30, 2028, and finally settles at 6.0x from December 31, 2028, onward [1]. Despite these upper limits, management maintains stricter internal targets, aiming to reduce the adjusted “Wholeco” leverage to below 5.5x by the end of 2026 and to approximately 5.0x by the close of 2028 [1].